HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
VRTX
Vertex Pharmaceuticals Incorporated
VRTX's fundamentals are strong, but it looks expensive: trading at 35x earnings, above its usual 28x. Analysts expect earnings to hold roughly steady, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
VRTX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Healthy | |
| Strong |
VRTX's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
VRTX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 23x | $360 | -34% |
| Fair | 28x | $429 | -21% |
| Forward | 29x | $543 | — |
| Expensive | 32x | $496 | -8.7% |
| Current | 35x | $543 | — |
Historical ranges are pointers, not guarantees.
VRTX's PE is in its expensive range at 35x. On analysts' estimates for next year's earnings, today's price would be 29x, in its fair range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
VRTX Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Stable | |
| Growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect VRTX's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
VRTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $18.81 | +21% |
| Q3 2026 | $15.53 | +8.6% |
| Q2 2026 | $17.17 | +22% |
| Q1 2026 | $16.85 | +$20.65 |
| Q4 2025 | $15.32 | +$17.40 |
| Q3 2025 | $14.30 | +$16.29 |
| Q2 2025 | $14.11 | +$16.14 |
| Q1 2025 | -$3.80 | -125% |
| Q4 2024 | -$2.08 | -115% |
VRTX has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over VRTX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
VRTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.4B | +12% |
| Q2 2026 | $3.3B | +12% |
| Q1 2026 | $3B | +7.8% |
| Q4 2025 | $3.2B | +9.5% |
| Q3 2025 | $3.1B | +11% |
| Q2 2025 | $3B | +12% |
| Q1 2025 | $2.8B | +3% |
| Q4 2024 | $2.9B | +16% |
VRTX's revenue has grown year over year every quarter since late 2020: $3.4B last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 21% | -18 points |
| Q2 2026 | 37% | -1.4 points |
| Q1 2026 | 38% | +15 points |
| Q4 2025 | 38% | +2.6 points |
| Q3 2025 | 39% | -1.7 points |
| Q2 2025 | 39% | +172 points |
| Q1 2025 | 23% | -20 points |
| Q4 2024 | 35% | -4 points |
VRTX has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over VRTX on cash flow, with more consistent year-over-year improvement.
VRTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $545.8M | -52% |
| Q2 2026 | $1B | +9.3% |
| Q1 2026 | $1.3B | +66% |
| Q4 2025 | $348.6M | -29% |
| Q3 2025 | $1.1B | -12% |
| Q2 2025 | $927.4M | +$4.8B |
| Q1 2025 | $778.2M | -37% |
| Q4 2024 | $492M | +179% |
VRTX generated $3.2B in free cash flow over the past year, down 4% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over VRTX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
VRTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | -0.9% | -2.4M shares |
| 3 years | -2.1% | -5.4M shares |
| 5 years | -1.7% | -4.5M shares |
| Available history | -2.6% | -6.9M shares |
VRTX has 255M diluted shares, down 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $126.7M |
| Q2 2026 | $469.5M |
| Q1 2026 | $336.9M |
| Q4 2025 | $128.4M |
| Q3 2025 | $1.1B |
| Q2 2025 | $391.8M |
| Q1 2025 | $426.1M |
| Q4 2024 | $417.9M |
VRTX spent $1.1B buying back its own shares over the past year, down 54% from the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
VRTX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.1x | Net Cash |
| Q2 2026 | -1.2x | Net Cash |
| Q1 2026 | -1.1x | Net Cash |
| Q4 2025 | -1.2x | Net Cash |
| Q3 2025 | -1.2x | Net Cash |
| Q2 2025 | -1.2x | Net Cash |
| Q1 2024 | -2.1x | Net Cash |
| Q4 2023 | -2.6x | Net Cash |
VRTX has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
VRTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.4 | Neutral |
| Stochastic | 81.1 | Overbought |
VRTX's weekly RSI is 59 (neutral) and its Stochastic is 81 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
VRTX PE vs Healthcare Sector
| Metric | VRTX | Sector median | Relative |
|---|---|---|---|
| PE | 35x | 26x | 35% above |
| PE % | 91 | 29 | 62 pts above |
VRTX is trading at 35x earnings, a 35% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
VRTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $526.7 | 3% above |
| 20 week MA | $516.4 | 5.1% above |
| 50 week MA | $479.2 | 13% above |
| 100 week MA | $459.7 | 18% above |
| 200 week MA | $428.4 | 27% above |
VRTX has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
VRTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $221.0 | $234.5 | +6.1% |
| 2021 | $234.5 | $223.5 | -4.7% |
| 2022 | $223.5 | $289.7 | +30% |
| 2023 | $289.7 | $406.9 | +40% |
| 2024 | $406.9 | $408.8 | +0.5% |
| 2025 | $408.8 | $462.9 | +13% |
| 2026 YTD | $462.9 | $542.6 | +17% |
VRTX has the edge over HIMS on returns for 2026, with the stronger performance.